1118 Chess Drive
About Orchard Therapeutics
Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to transforming the lives of patients with rare disorders through innovative gene therapies
Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders
We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy
Our mission is to be a leading global, fully integrated company delivering innovative gene therapies that transform the lives of patients with rare disorders
18 articles with Orchard Therapeutics
Despite strong sales of shingles vaccine Shingrix, GlaxoSmithKline reported its sales and earnings fell 2 percent in the first quarter of the year, largely due to challenges in respiratory sales as well as significant currency impact.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to trim excess fat from the company. This morning the company announced it has divested its rare disease gene therapy portfolio to Orchard Therapeutics.
Dr. Malech is a globally recognized expert in primary immune deficiencies and gene therapy.
Orchard Therapeutics today announced the appointment of Frank Thomas to the newly created position of CFO and CBO.
Orchard Therapeutics today announced that Mark Rothera, president and CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018 at 3:00 p.m. PT.
12/20/2017Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.
Yposkesi Has Been Selected by Orchard Therapeutics to Produce Lentiviral Gene Therapy Vectors For Clinical Trials
As part of this partnership, Yposkesi will produce lentiviral vector batches to meet Orchard's needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous disease.
Orchard Therapeutics and Généthon Announce Gene Therapy Alliance in X-Linked Chronic Granulomatous Disease
X-linked CGD is a primary immune deficiency resulting from a mutation on the X-chromosome and affecting mainly boys.
Orchard today announced the opening of a second facility for technical operations in the San Francisco Bay Area.
Orchard Therapeutics Announces Extension of its Collaboration with Manchester University to Include Sanfilippo Syndrome Type B
Orchard Therapeutics announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B from The University of Manchester, UK.
Orchard Therapeutics Announces A Manufacturing Services Agreement With PCT Cell Therapy Services, LLC
Orchard Therapeutics And UCLA Receive $20 Million In Latest Round Of Funding From California's Stem Cell Agency
Orchard Therapeutics Announces Presentations From University College London/GOSH And UCLA Academic Collaborators On Clinical Data In ADA-SCID Using Ex-Vivo Lentiviral Gene Therapy At September 2016 ESID And ESGCT Congresses